본문 바로가기

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
BONE MARROW TRANSPLANTATION54(12) · pp.2051 · 2019
피인용
Web of Science 5Scopus 4
FWCI (Scopus)
0.17
JCR IF
JCR 2018 4.674
ISSN
0268-3369

저자

  1. Lee, Yoo Jin제1저자Department of Internal Medicine, Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
  2. Moon, Joon HoDepartment of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
  3. Sohn, Sang KyunDepartment of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
  4. Kim, Seok JinDepartment of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  5. Jung, Sung-HoonDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
  6. Lee, Je-JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
  7. Jo, Jae-CheolDepartment of Internal Medicine, Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
  8. 신호진Department of Internal Medicine, Division of Hematology-Oncology, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
  9. Lee, Won SikDepartment of Hematology-Oncology, Inje University Busan Paik Hospital, Busan, Republic of Korea
  10. Lee, Ji HyunDepartment of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Republic of Korea
  11. Bae, Sung HwaDepartment of Hematology-Oncology, Daegu Catholic University Hospital, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea
  12. Kim, Min KyoungDepartment of Hematology-Oncology, Yeungnam University Medical Center, Daegu, Republic of Korea
  13. Lee, Ho SupDepartment of Internal Medicine, Division of hematology, Kosin University College of Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea
  14. Kim, Kihyun교신저자Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  15. Min, Chang-KiDepartment of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

초록

Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of upfront ASCT are still debated. We investigated if two additional cycles of VTD (VTD6) improved the responses and progression-free survival (PFS) compared with four cycles of VTD (VTD4). We retrospectively reviewed outcomes of 190 NDMM patients treated with at least four cycles of VTD followed by ASCT between September 2014 and August 2017 [VTD4, n = 129 (67.9%); VTD6, n = 61 (32.1%)]. The VTD6 group had a higher pre-ASCT complete response (CR) rate than the VTD4 group (31.1% versus 10.1%, P < 0.001), but, the pre- and post-ASCT >= very good partial response (VGPR), and 2-year PFS were similar. Multivariate analysis revealed age, beta(2)-microglobulin, and pre-ASCT CR as important factors for PFS. Two additional cycles of VTD prolonged PFS in patients with PR only after VTD4 [Hazard ratio (HR) = 0.29, P = 0.016] or those with Revised International Staging System stage I/II (HR = 0.36, P = 0.039). In conclusion, two additional VTD cycles may be helpful for patients with PR only after VTD4 but high risk MM needs the other treatment options.

키워드

STEM-CELL TRANSPLANTATIONTHALIDOMIDE PLUS DEXAMETHASONECOMPLETE REMISSIONINTENSIVE THERAPYBORTEZOMIBSURVIVALCRITERIAIMPACT

식별자

Scopus EID
2-s2.0-85069903681
WoS UID
000500920000017